Papp L A, Sinha S S, Martinez J M, Coplan J D, Amchin J, Gorman J M
Biological Studies Unit, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA.
Psychopharmacol Bull. 1998;34(2):207-9.
Venlafaxine, a structurally novel antidepressant that combines mechanisms of action of both the cyclic antidepressants and SSRIs, may be effective in the treatment of panic disorder. Thirteen patients with DSM-IV panic disorder with or without agoraphobia participated in an open-label, fixed-flexible dose treatment study with venlafaxine. All patients who completed the 10-week trial exhibited statistically significant decreases in scores on anxiety symptoms as well as complete cessation of panic attacks at an effective mean daily dose of 47 mg per day. Venlafaxine was well tolerated in all completers. Venlafaxine may be an effective antipanic agent, even at lower than typical antidepressant dosages.
文拉法辛是一种结构新颖的抗抑郁药，它结合了环类抗抑郁药和选择性5-羟色胺再摄取抑制剂（SSRI）的作用机制，可能对惊恐障碍有效。13例患有或未患有广场恐惧症的DSM-IV惊恐障碍患者参与了一项文拉法辛开放标签、固定-灵活剂量治疗研究。所有完成10周试验的患者焦虑症状评分均有统计学意义的下降，且每日有效平均剂量为47毫克时惊恐发作完全停止。所有完成试验的患者对文拉法辛耐受性良好。即使低于典型抗抑郁药剂量，文拉法辛也可能是一种有效的抗惊恐药物。
